U.S. Stem Cell, Inc.
U.S. Stem Cell, Inc. (USRM): 3 pipeline candidates · 1 clinical trial. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E -1.00 · 0% dilution
Lead: Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for U.S. Stem Cell, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$64K
Cash
$5K
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| adipocell | Phase 1 |
| myocell | Phase 3 |
| myocell sdf-1 | Phase 1 |
Frequently asked questions
How many drug candidates are in U.S. Stem Cell, Inc.'s pipeline?
U.S. Stem Cell, Inc. (USRM) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is U.S. Stem Cell, Inc.'s lead drug candidate?
U.S. Stem Cell, Inc.'s most advanced tracked candidate is adipocell (Phase 1) for Acute myocardial infarction, chronic heart ischemia, and lower limb ischemia.
What is U.S. Stem Cell, Inc.'s market capitalization?
U.S. Stem Cell, Inc.'s market capitalization is approximately $64K.
Who is the CEO of U.S. Stem Cell, Inc.?
Mr. Michael Tomas is the chief executive officer of U.S. Stem Cell, Inc. (USRM).
Get the full picture on U.S. Stem Cell, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.